Ross Labs
This article was originally published in The Tan Sheet
Executive Summary
Abbott Senior VP-Finance and Chief Financial Officer Gary Coughlan tells May 10 session at Alex. Brown investment conference that the company's nutrition R&D is "focusing on improved pediatric formulas, new disease-specific products" like the medical nutritional Advera, and "new packages and systems" for existing products. He noted that the company's medical nutritional sales increased 15% in 1993 to $850 mil., and that Abbott maintains its leadership position in hospitals, nursing homes and retail outlets
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning